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Abstract
Purpose of Review Over the last years, our understanding of the molecular biology of
pediatric brain tumors has vastly improved. This has led to more narrowly defined
subgroups of these tumors and has created new potential targets for molecularly driven
therapies. This review presents an overview of the latest advances and challenges of
implementing targeted therapies into the clinical management of pediatric brain tumors,
with a focus on gliomas, craniopharyngiomas, and medulloblastomas.
Recent Findings Pediatric low-grade gliomas (pLGG) show generally a low mutational
burden with the mitogen-activated protein kinase (MAPK) signaling presenting a key
driver for these tumors. Direct inhibition of this pathway through BRAF and/or MEK
inhibitors has proven to be a clinically relevant strategy. More recently, MEK and IL-6
* The Author(s) 2020. This article is an open access publication
receptor inhibitors have started to be evaluated in the treatment for craniopharyngiomas.
Aside these low-grade tumors, pediatric high-grade gliomas (pHGG) and medulloblasto-
mas exhibit substantially greater molecular heterogeneity with various and sometimes
unknown tumor driver alterations. The clinical benefit of different targeted therapy
approaches to interfere with altered signaling pathways and restore epigenetic dysregu-
lation is undergoing active clinical testing. For these multiple pathway-driven tumors,
combination strategies will most likely be required to achieve clinical benefit.
Summary The field of pediatric neuro-oncology made tremendous progress with regard to
improved diagnosis setting the stage for precision medicine approaches over the last
decades. The potential of targeted therapies has been clearly demonstrated for a subset of
pediatric brain tumors. However, despite clear response rates, questions of sufficient
blood-brain barrier penetration, optimal dosing, treatment duration as well as mecha-
nisms of resistance and how these can be overcome with potential combination strategies
need to be addressed in future investigations. Along this line, it is critical for future trials
to define appropriate endpoints to assess therapy responses as well as short and long-term
toxicities in the growing and developing child.
Introduction
Central nervous system (CNS) tumors are the most
common type of solid tumors in children [1]. Tradition-
ally, standard therapy for these tumors consists of sur-
gery and/ or chemotherapy as well as radiotherapy. Even
though there is a growing number of pediatric brain
tumors in which tumor growth can be controlled or
even cured, these therapies expose children to high doses
of chemotherapy and radiation, leading to long-term
effects that negatively impact quality of life [2]. There-
fore, therapeutic approaches that target specific molecu-
lar tumorigenic pathways (Fig. 1) and pose fewer side
effects are needed in the clinical management of pediat-
ric brain tumors.
Over the last decade, the understanding of the mo-
lecular biology of pediatric brain tumors has expanded
due to the emergence of genomic platforms [3–5, 6••].
This has led to more narrowly defined molecular tumor
subgroups and created a new opportunity for targeted
therapies (Table 1). Even in tumors that were mainly
treated with surgery and/or radiotherapy, e.g., cranio-
pharyngiomas, new insights into oncogenic upregula-
tion of signaling pathways are now being used for
biology-derived therapeutic interventions. Besides the
growing number of trials testing these targeted agents
(Table 2), several recent studies have demonstrated the
feasibility and utility of incorporating molecular profil-
ing into the daily clinical care of children with brain
tumors, allowing treatment decision-making based on
specific molecular alterations in real time [7, 8•].
In this article, we will highlight the latest advances
and challenges of implementing targeted therapies into
the clinical management of pediatric brain tumors with
a focus on gliomas, craniopharyngiomas, and
medulloblastomas.
Low-Grade Gliomas
Pediatric low-grade gliomas (pLGGs) are the most common childhood CNS
tumors, accounting for approximately one-third of pediatric brain tumors [9].
Pediatric LGGs are a heterogeneous group of lesions histologically classified as
WHO grade I–II tumors, including but not limited to pilocytic astrocytoma (PA),
diffuse astrocytoma, subependymal giant cell astrocytoma (SEGA), and pleomor-
phic xanthoastrocytoma (PXA) (Table 1) [3]. Prognosis for pLGG is generally very
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Fig. 1. Important signaling pathways and their inhibitors in pediatric brain tumors (A: pLGG, pHGG and craniopharyngioma; B:
diffuse midline glioma; C: medulloblastoma).A1 Constitutive RAS/MAPK and RAS/PI3K/AKT/mTOR pathway activation and
corresponding inhibitors. Pathway activation takes place through paracrine stimulation (craniopharyngioma), activating mutation/
fusion in RTK, BRAF, PI3K and TSC1/2 or loss of NF1 (pHGG, pLGG) and propagates cell growth and cell survival. A2 CDK4/6 inhibition
prevents cell cycle progression from the G1 phase to the S phase. B1 Epigenetic modifications in H3K27M mutated DMGs and HDAC
inhibition. The mutated histone site H3K27M inactivates PRC2. The resulting hypomethylation at H3K27 enhances oncogenic
transcription activation at these loci. By inhibiting HDAC, histone tail poly-acetylation can be achieved and partially rescue
H3K27M-induced global hypomethylation, by counteracting PRC2 inhibition. B2 ONC inhibition pathway in DIPG. ONC drugs are
thought to induce apoptosis either by antagonizing DRD2 receptors, or through targeting and activating the mitochondrial ClpP
protein. Regardless, both mechanisms result in ATF4 increased expression. ATF4-driven CHOP expression results in TRAIL pathway
activation by recruiting DR5 receptors which leads to cell death. C1 Alterations in the hedgehog signaling pathway in SHH
medulloblastomas and corresponding inhibitors. In the absence of HH ligand, PTCH1 inhibits SMO and hedgehog signaling does not
take place. In the activated HH pathway (e.g. through HH binding, gain of function mutation in SMO or loss of function mutation in
PTCH1/SUFU) the transcription factor GLI is activated resulting in the expression of HH targeted genes. C2 Epigenetic modifications
in Group 4 medulloblastomas and EZH2 inhibition. The over-expressed EZH2 (catalytic subunit of PRC2) methylates H3K27 and
thereby promotes repression of transcription at these loci. The subsequent repression of tumor suppressor genes is further enhanced
by the loss of function of the mutated demethylase KDM6A. EZH2 inhibitors are used to repeal this repressive methylation signature.
(Figure created with BioRender.com)
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favorable, with 10-year overall survival (OS) between 85 and 96% [10]. If
feasible, initial therapy for these low-grade tumors often relies on maximal safe
surgical resection. Historically, unresectable pLGGs, or those that progressed after
initial resection, were retreated with additional therapies consisting often of
cytotoxic chemotherapy or, if unavoidable, radiation therapy [9].
Table 2. Molecular targets and their corresponding clinical trials for pediatric brain tumors
Molecular target Drug Disease Upfront/recurrent Trial Phase
BRAF Vemurafinib Glioma (BRAF-mut) Recurrent NCT01748149 1
PLX8394 Solid tumor (BRAF-mut) Recurrent NCT02428712 1/2
TAK-580 LGG Recurrent NCT03429803 1/2
MEK Selumetinib LGG (NF1 associated) Upfront NCT03871257 3
Selumetinib LGG (non-NF1 associated) Upfront NCT04166409 3
MEK162 LGG (NF1 or BRAF-fusion) Recurrent NCT02285439 1/2
Trametinib LGG (NF1 or BRAF-fusion) Recurrent NCT03363217 1/2
BRAF/MEK Dabrafenib/ LGG (BRAF-mut)/ HGG Upfront/recurrent NCT02684058 2
trametinib HGG (BRAF-mut) Upfront NCT03919071 2
Vemurafenib/cobimetinib PCP (BRAF-mut) Upfront NCT03224767 2
IDH AG881 Glioma (IDH-mut) Recurrent NCT02481154 1
AG-120 Glioma (IDH-mut) Recurrent NCT02073994 1
PARP BGB-290 LGG/HGG (IDH-mut) Recurrent/upfront NCT03749187 1
CDK4/6 Palbociclib-isethionate CNS-tumors Recurrent NCT02255461 1
Abemaciclib HGG Recurrent NCT02644460 1
Ribociclib CNS-tumors Recurrent NCT03434262 1
NTRK Larotrectinib Solid tumors (incl. CNS) Recurrent NCT03213704 2
Larotrectinib Solid tumors (incl. CNS) Recurrent NCT02637687 1/2
Larotrectinib Solid tumors (incl. CNS) Recurrent NCT02576431 2
Entrectinib Solid tumors (incl. CNS) Recurrent NCT02650401 1/2
MET PLB1001 HGG Recurrent NCT02978261 1
PI3K/mTOR LY3023414 Solid tumors (incl. CNS) Recurrent NCT03213678 2
Paxalisib DMG Upfront NCT03696355 1
HDAC Panobinostat DIPG Recurrent NCT02717455 1
Panobinostat HGG (H3K27M) Recurrent/upfront NCT03632317 1
Fimepinostat HGG, medulloblastoma Recurrent/upfront NCT03893487 1
MTX110 DIPG Upfront NCT03566199 1/2
DRD2/ClpP ONC201 HGG (H3K27M) Recurrent/upfront NCT03416530 1
IL-6 receptor Tocilizumab ACP Recurrent/upfront NCT03970226 1
SMO receptor Vismodegib MB Upfront NCT01878617 2
CK2 Silmitasertib (CX-4945) MB Recurrent NCT03904862 1/2
EZH2 Tazemetostat CNS-tumors Recurrent NCT03155620 2
BET proteins BMS-986158 Solid tumors (incl. CNS) Recurrent NCT03936465 1
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Pediatric LGGs show a lowmutational burden and are generally considered
to be a single molecular pathway disease. The mainmolecular pathway affected
in these tumors is the mitogen-activated protein kinase (MAPK) signaling
cascade (Fig. 1). The most frequent alterations affecting this pathway include
BRAF fusions or the point mutation BRAF V600E [6••, 11, 12]. Alterations
within the PI3K/AKT/mTOR signaling pathway have also been described driv-
ing tumorigenesis in pLGGs (Fig. 1) [13].
TSC1/2 Mutations and mTOR Inhibitors
The first and well-established targeted therapy for pediatric brain tumors refers to
the use of everolimus for SEGAs in patients with tuberous sclerosis complex (TSC).
TSC is a genetic neurocutaneous syndrome caused by inactivatingmutations in the
TSC1 or TSC2 gene. About 10% of patients with TSC develop these slow-growing,
low-grade SEGAs, which mainly arise in the periventricular area [14].
TSC1 and TSC2 encode the proteins tuberin and hamartin, respectively.
These proteins form the tuberin-hamartin complex, which negatively regulates
the mTOR pathway. By consequence, mutations in either TSC1 or TSC2 lead to
unchecked activation of mTOR and thereby drive cell proliferation and survival
(Fig. 1) [15]. Krueger et al. showed that the mTOR inhibitor everolimus safely
and significantly reduced tumor volume of SEGAs [16]. Even after 5 years,
everolimus remained well-tolerated and continued to demonstrate sustained
effect on tumor volume reduction. The treatment is now a US Food and Drug
Administration-approved therapy for SEGAs and is considered the standard of
care of these tumors if surgical resection is not feasible [17].
Loss of NF1 and mTOR/MEK Inhibitors
More recently, everolimus has also been used for the treatment of PAs. These
tumors are the principal CNS neoplasm associated with the tumor predisposi-
tion syndrome Neurofibromatosis type 1 (NF1) [3]. The NF1 gene encodes the
neurofibromin protein, which acts in the MAPK pathway as a GTPase for RAS,
thereby facilitating the deactivation of RAS (Fig. 1). Patients withNF1 have only
one wildtype copy of the NF1 gene. Subsequent functional loss of this single
wildtype NF1 gene results in overactivity of the Ras effector pathways via the
RAS/MAPK or RAS/PI3K/AKT/mTOR pathway [18, 19].Therefore, these NF1-
associated pLGG tumors seem to benefit from MAPK signaling blockage by
MEK inhibitors like selumetinib [20]. On the other hand, Ullrich et al. recently
showed that patients with recurrent/progressive NF1-associated pLGG undergo
significant disease stability or shrinkage by successfully blocking the RAS/PI3K/
AKT/mTOR signaling pathway with mTOR inhibitor everolimus [21••]. Since
everolimus is very well tolerated and therefore provides a good quality of life for
patients, a follow-up study from the Pacific Pediatric Neuro-Oncology Consor-
tium (PNOC) is enrolling children with recurrent LGG and actively investigat-
ing tissue biomarkers of response (PNOC001; NCT01734512).
BRAF Alterations (Mutation/Fusion) and BRAF/MEK Inhibitors
BRAF gene alterations are frequently observed in pLGGs such as PAs, ganglio-
gliomas (GGs) or PXAs. The BRAF gene encodes the serine/threonine kinase B-
Raf, a downstream effector in the MAPK signaling pathway (Fig. 1) [3, 22].
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PAs, the most common glial tumor in children, harbor a tandem duplica-
tion of 7q34 involving the BRAF gene in 9 70% of cases. Due to this duplica-
tion, the N-terminal regulatory region of BRAF is replaced by the N-Terminus of
the KIAA1549 protein resulting in KIAA1549-BRAF fusion protein, which forms
BRAF dimers and constitutively activates the MAPK pathway [3, 12].
On the other hand, PXAs show constitutive activation of the MAPK signaling
pathway by an amino acid substitution of valine to glutamate (V600Emutation)
within the BRAF gene, leading to a monomeric BRAF oncoprotein. Even though
the BRAF V600E mutation is common in PXA (9 60%), it also occurs in other
pLGGs such as PA (2–9%) and GGs (up to 18%) [23]. Since KIAA1549-BRAF
fusion and the BRAF V600E mutation are key oncogenic drivers in pLGGs, they
represent a particularly good target for either MEK or BRAF inhibitors [22, 24].
Dabrafenib, a BRAF V600E inhibitor, has been described as a promising
treatment option in BRAF V600E-mutated PXAs in single cases [25]. Hargrave
et al. demonstrated in a phase I/II trial a meaningful clinical benefit of dabra-
fenib in relapsed or refractory BRAF V600E pLGGs, where 44% of the tumors
radiographically responded to this targeted therapy [26]. Nicolaides et al.
reported that vemurafenib was well tolerated in a phase I trial for a selected
group of recurrent/refractory BRAF V600E mutated brain tumors with good
responses as well [27] (PNOC002; NCT01748149).
However, BRAF V600E inhibitors can lead to paradoxical activation of the
MAPK pathway in tumor cells with BRAF wildtype or cells harboring BRAF fusions
[28–30], demonstrating the critical issue selecting the correct patient population for
such therapies. Besides adequate patient selection, the effects of paradoxical MAPK
pathway activation have been overcome with the use of second-generation BRAF
inhibitors like TAK-580 (also known as MLN2480). TAK-580 is a pan-RAF inhib-
itor and an equipotent antagonist of BRAFmutated (monomeric) and BRAF fusion
(dimeric) oncoproteins. Beside the capacity to eliminate the paradoxical activation
of the MAPK pathway, this second-generation pan RAF inhibitor also harbors a
favorable blood-brain barrier penetration compared with first-generation agents
and an agreeable administration schedule with once weekly dosing [31•]. Clinical
trials, under development and in progress, will examine the use of second-
generation BRAF inhibitors in children and adults with BRAF-mutated malignan-
cies (NCT03429803, NCT02428712).
With regard to paradoxical activation of MAPK signaling and the potential
toxicity of BRAF inhibitors, there have also been efforts to target more down-
stream MAPK pathway components, such as MEK. MEK inhibitor selumetinib
has proven to be an effective and reasonably well tolerated orally available
inhibitor for the treatment of pLGGs [32]. Fangusaro et al. recently demonstrat-
ed that the use of single-agent selumetinib for BRAF-altered recurrent PAs
resulted in a sustained partial tumor response rate of 36% (9/25 patients) and
for NF1-associated recurrent pLGGs in one of 40% (10/25 patients) [20]. While
other phase I/II trials investigate alternative MEK inhibitors (NCT02285439,
NCT03363217) in the recurrent setting, two phase III trials testing selumetinib
for newly diagnosed patients. In these phase III trials, selumetinib will be
compared with standard chemotherapy with carboplatin/vincristine for
patients with NF1-associated pLGG (NCT03871257) or with non-NF1 pLGG
(NCT04166409). Along these lines, another phase III study, the LOGGIC trial,
will randomize also newly diagnosed pLGG (non-NF1) participants to chemo-
therapy (carboplatin/vincristine vs. weekly vinblastine) vs. trametinib. This trial
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will use both functional endpoints as well as overall and progression free
survival to compare treatment benefit. These studies will answer the question
how these targeted inhibitors compare to standard chemotherapy regimens
with the important aspect of taking functional endpoints into consideration.
In addition to single-agent use of BRAF or MEK inhibitors, the combination
of both MAPK pathway inhibitors has been used with promising results in the
treatment of other tumors. In recent years, the combined use of BRAF and MEK
inhibitors for the treatment of BRAF V600E mutated melanomas has shown
significant OS benefit without increasing overall toxicity [33]. Published 5-year
follow-up data also support these findings from a long-term perspective [34].
With regard to pLGG, Zhang et al. showed in vitro as well as in vivo that
combined BRAF and MEK inhibition prevents rebound MAPK activation,
resulting in enhanced antitumor efficacy [35]. This combinatorial targeting
approach is now in clinical trials for pLGG as well as high-grade glioma
(NCT02684058, NCT03919071).
Other promising combinatory targeting strategies to target the MAPK path-
way and address the potential escape mechanisms of acquired resistance to
single-agent MAPK pathway therapies include using a mTOR inhibitor along
with MEK inhibition. Two independent studies were able to show the preclin-
ical potency of combinatorial targeting with MEK and mTOR inhibitors, which
will be tested in an upcoming trial for recurrent pLGGs within PNOC
(PNOC021; NCT04485559) [36, 37••].
High-Grade Gliomas
Pediatric high-grade gliomas (pHGGs) include WHO grade III and grade IV
tumors and comprise approximately 10–15% of all primary brain tumors in
children (Table 1) [3]. Unfortunately, the prognosis for pHGGs has been
stagnant despite several decades of clinical trial investigations. Survival remains
extremely poor with a median OS of 10 to 18 months, resulting in one of the
leading causes of pediatric cancer deaths [3]. Standard of care for pHGG
historically relies on maximal safe surgical resection followed by adjuvant
chemotherapy and focal radiation [38].
Although the histopathological appearance of pHGG overlaps with their adult
counterparts, pediatric HGGs harbor different genetic alterations and should there-
fore be considered separate tumor entities [4, 39]. Based on the regional occurrence,
pHGG can be separated into midline and non-midline, hemispheric HGGs.
Midline tumors occur in the thalamus, brainstem, or spine. Malignant midline
gliomas are referred to as diffusemidline gliomas (DMGs) that also include diffuse
intrinsic pontine gliomas (DIPGs). Over 70% of these DMGs harbor recurrent
mutations in genes encoding histoneH3 variants including histoneH3.3 (H3F3A)
and H3.1 (HIST1H3B and HIST1H3C). Therefore, the new WHO classification
introduced a new entity referred to as diffuse midline glioma, H3K27 mutant. In
contrast, the H3G34R/V (glycine to arginine or valine) missense mutations can
mainly be found in hemispheric HGGs and rarely in DMGs [39, 40]. As expected,
compared with pLGGs, pHGG exhibit substantially greater genetic heterogeneity.
Genetic analyses of pHGGhave uncovered frequentmolecular alterations targeting
receptor tyrosine kinase (RTK) signaling pathways (e.g., PDGFRA, MET, FGFR1,
PIK3CA, BRAF) and cell cycle regulation (e.g., TP53, ATRX, CDK4/6, CDKN2A)
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(Table 1) [4, 5]. However, some of these genetic changes tend to occur within
subgroups of pHGGs. For example, DIPGs harbor recurrent somatic mutations in
ACVR1 (35%), while infant hemispheric HGGs encompass tumors driven by
NTRK, ALK, ROS1, and MET fusions [41, 42]. A detailed understanding of these
different molecularly distinct subtypes of pHGGs will be critical when assessing
treatment responses or failures as these alterations might impact outcome.
IDH Mutation and PARP Inhibitors
In adults, HGGs are currently subdivided into either IDH wildtype or IDH
mutant gliomas [3]. The IDH mutation is also present in a subset of pediatric
patients, suggesting that these lesions may be biologically similar to malignant
adult gliomas [43, 44].
The normal function of isocitrate dehydrogenase (IDH) enzymes is to
catalyze the conversion of isocitrate to α-ketoglutarate in the citric acid cycle.
Nearly all known IDH1/2 alterations are heterozygous missense mutations that
confer a neomorphic activity on the encoded IDH enzymes, such that they
convert the α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2HG)
[45]. There is growing evidence that 2HG affects chromatin methylation and
cellular differentiation [46]. It is also assumed that 2HG promotes deficiency in
homologous recombination (HR) within the IDH-mutated cancer cells [47].
For adults, a number of clinical trials are investigating the benefit of IDH1
inhibitors in IDHmutant gliomas, hoping that these patients would benefit from
reduction of the oncometabolite 2HG (NCT02481154, NCT02073994).In con-
trast, the finding that IDH1/2mutations induce a HR defect within tumor cells led
to the concept of exploiting rather than inhibiting the effects of the IDHmutation
through the use of poly(adenosine 5′-diphosphate-ribose) polymerase (PARP)
inhibition [48••]. Normal cells can tolerate DNA damage generated by PARP
inhibition because of an efficientHRmechanism.Meanwhile, IDHmutated cancer
cells demonstrate a deficient HR pathway and are thus unable to repair double-
strand breaks efficiently [47]. Exploiting the concept of synthetic lethality, a current
phase I trial is evaluating the side effects and best dose of the CNS penetrant PARP
inhibitor, BGB-290, in combination with temozolomide in treating adolescents
and young adults with IDH1/2-mutant grade I-IV gliomas (PNOC017;
NCT03749187).
BRAF Mutation and BRAF/MEK Inhibitors
BRAF point mutations are present in about 10–15% of pHGG [49]. It is
assumed that these tumors may represent a subset of pLGG that transformed
into secondary high-grade gliomas [50]. The BRAF mutations often co-occur
with deletions of CDK inhibitor 2A (CDKN2A) and together contribute to
dysregulated cellular proliferation [51]. These tumors are associated with mod-
estly improved OS when compared with primary HGGs [5].
Case reports and series have revealed promising results using BRAF inhib-
itors as monotherapy or, more recently, in combination with MEK inhibitors
for BRAF V600E mutant pHGG tumors [52–54]. In a case series of 3 patients,
Toll et al. showed that the combination of BRAF V600E andMEK inhibitor therapy
is an effective and safe treatment option for children with these BRAF V600E
mutated HGG [49]. Clinical trials are now testing this strategy for newly diagnosed
and recurrent BRAF V600E mutant HGGs (NCT02684058, NCT03919071).
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The combination of a BRAF inhibitor with a CDK4/6 inhibitor, which
prevents progression from the G1 phase to the S phase of the cell cycle (Fig.
1), has shown improved survival in human xenograft models of pHGG with
BRAF V600E mutation and CDKN2A homozygous loss compared with single-
agent therapy [55]. This combination has not yet been evaluated in clinical trials
in pHGGbutmay represent a promising targeted therapeutic strategy option for
patients harboring both alterations. Currently, two phase I clinical trials are
evaluating the safety and efficacy of CDK4/6 inhibitor monotherapy in pediat-
ric tumors, including pHGGs (NCT02255461, NCT02644460).
Receptor Tyrosine Kinase (RTK) Signaling Aberrations and NTRK, MET, and PI3K/mTOR
Inhibitors
Common signaling pathways that are activated in pHGGs include RTK/PI3K/
AKT/mTOR andMAPK cascades. These pathways are activated through different
mutations, fusions, or amplifications with genes coding for RTKs. In addition,
the PI3K/AKT/mTOR pathway is also activated by other somatic variations such
as the PIK3CAmutation, coding for the intracellular signal transducer PI3K (Fig.
1) [56]. Recent studies suggest that a large subset (20–30%) of pediatric patients
with pHGG have mutations and/or amplifications of platelet-derived growth
factor receptor alpha (PDGFRA) [4]. Other in-frame fusions of RTK genes
involve the ALK, ROS1, FGFR, MET, and NTRK genes, and one recent study
revealedMET fusions in 10% andMET amplification in 3–7%of pHGG [4, 57].
Lastly, neurotrophic receptor kinase gene (NTRK) fusions have been identified
in up to 40% of hemispheric HGG in infants [4, 41, 42].
Several case reports have been published demonstrating the efficacy
of targeting ROS1, FGFR, NTRK, and MET gene fusions in pHGGs [57–
60], but with regard to the proof of efficacy, data from clinical trials is
lacking for many of these RTK inhibitors. Success in NTRK fusion
inhibition is largely drawn from larotrectinib, a highly selective TRK
inhibitor that is well tolerated in pediatric patients and has shown
significant antitumor activity in patients with TRK fusion positive can-
cers [61]. Clinical trials to further assess the efficacy and safety of
larotrectinib in up-front and recurrent pediatric malignancies, including
pHGGs, are ongoing (NCT03213704, NCT02637687, NCT02576431).
Along these lines, a phase 1 study using entrectinib, a new-generation
CNS-penetrant oral inhibitor of ALK/ROS1/NTRK kinases, has been suc-
cessfully concluded in refractory CNS tumors harboring alterations in
these kinases [62, 63]. A phase II trial investigating the safety and
efficacy of entrectinib is ongoing (NCT02650401).
Bender et al. were also able to show that MET inhibitors suppress MET-
driven tumor growth in xenograft models and achieved partial response with
the targeted inhibitor, crizotinib, in a pediatric patient bearing an MET fusion
expressing glioblastoma [57]. Furthermore, the selective MET inhibitor,
PLB1001, is currently being tested in a clinical trial for PTPRZ1-MET fusion
gene positive recurrent HGG (NCT02978261).
The development of PI3K inhibitors for patients harboring a PI3K activating
mutation (e.g., PIK3CA mutation) has been difficult due to severe side effects
[64]. For pediatric patients harboring such a mutation, the targeted utilization
of everolimus has been applied and, more recently, LY3023414, a dual PI3K
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and mTOR inhibitor, is undergoing investigation (NCT03213678). Further-
more, paxalisib (GDC-0084) is another PI3K/mTOR inhibitor, which has re-
cently proven to penetrate the blood-brain barrier and showed a metabolic
partial response, by FDG-PET, in up to 26% of adult HGG patients [65]. A first-
in-pediatric study is currently examining the safety and preliminary antitumor
activity of paxalisib in DMGs (NCT03696355).
H3K27M Mutation and Histone Deacetylase (HDAC) Inhibitors
Trimethylation at H3K27 (H3K27me3) is associated with transcriptionally
silenced chromatin (Fig. 1). The H3K27M mutation in DMG prevents methyl-
ation by the repressive histonemethyl transferase (HMT) complex PRC2, which
results in hypomethylation of H3K27 leading to transcriptional activity at these
loci (Fig. 1) [66]. In order to re-establish the balance of these post-translational
modifications, it has been shown that in H3K27M mutant tumors, the histone
3 tail poly-acetylation can partially rescue H3K27M-induced hypomethylation,
by re-enabling PRC2-mediated histone methylation [67, 68]. By inhibiting
histone deacetylase (HDAC), for example, with panobinostat, poly-
acetylation can be achieved, and increased global H3K27 trimethylation can
be observed (Fig. 1) [69]. Currently, the safety of panobinostat and other
HDACs for the use in DIPG patients are being evaluated in phase 1/2 trials
(NCT02717455, NCT03632317, NCT03893487).Due to the fact that panobi-
nostat and other HDAC inhibitors have poor blood-brain barrier penetration, a
new water-soluble formulation (MTX110), which can be delivered directly to
the tumor through convection-enhanced delivery, has been developed [70] and
is currently being tested in a clinical trial for DIPG (PNOC015; NCT03566199).
H3K27M Mutation and the Impiridone, ONC201
In addition to HDAC inhibitors, the small anti-cancer imipridone, ONC201,
has shown preliminary but promising pre-clinical and clinical results in
H3K27M mutated pHGG. ONC201 is thought to induce cell death through
pro-apoptotic TRAIL pathway activation either by antagonizing dopamine
receptor D2 (DRD2) or by targeting and activating the mitochondrial casein-
olytic protease P (ClpP) protein (Fig. 1) [71, 72].
Recent preclinical data demonstrate that ONC201 ismost potently cytotoxic
to H3K27M mutant glioma cells with reduced activity against wild-type cells
[73]. Among the 17 patients included in a Phase II clinical trial of oral ONC201
in adult patients with recurrent glioblastoma, one 22-year-old patient harbored
a biopsy-proven H3K27M mutated thalamic high-grade tumor and showed
radiological tumor regression of approximately 80% [74]. Hall et al. success-
fully used ONC201 in a pediatric case of H3K27M-mutated DIPG and were
able to detect a significant radiological as well as clinical response [75]. These
promising results for ONC201 are currently being investigated in a clinical trial
for H3K27M-mutated pHGG (NCT03416530).
Craniopharyngiomas
Craniopharyngiomas (CPs) are histologically WHO grade I tumors with
two clinicopathological variants (adamantinomatous [ACPs] and papil-
lary [PCPs]) that harbor distinct phenotypes and genetic alterations
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(Table 1) [3]. Even though CPs are histologically benign, they are locally
aggressive tumors in the sellar region, which may cause devastating
visual, neurological, and endocrine deficits. ACP is the more prevalent
subtype and has a bimodal age distribution, with incidence peaks be-
tween ages 5–15 years and 45–60 years, whereas rare cases during the
neonatal period have been reported [76]. PCP, on the other hand, has
been classically considered an adult entity peaking between 40 and
55 years of age [77] and few pediatric cases being reported [78].
In general, CPs have traditionally been treated with surgery and/or radio-
therapy. Although the 10-year survival with these approaches is very good
(ranging from 64 to 92%), in the case of tumor progression or recurrence, the
therapeutic options are limited. Even with surgery or radiotherapy, CPs can
cause highmorbidity and predispose children to a life of severe disability across
different organ systems [79, 80].
The recent increase in knowledge of the molecular pathology of these
tumors and development of animal models have led to promising new possi-
bilities for the use of specific targeted therapies in the upfront and adjuvant
treatment of CPs [81].
BRAF Mutation and BRAF/MEK Inhibitors in PCP
Nearly all PCPs harbor the BRAF V600E mutation [82]. These findings
have led to a number of case reports using BRAF and/or MEK inhibitors
for CPC [83–85]. These case reports support the potential benefit of
BRAF inhibitors with or without the combination of MEK inhibitor in
the treatment of recurrent PCP. In all described cases, at least a transient
tumor response has been observed. For the first time, Jurtali et al.
administered the BRAF V600E inhibitor, dabrafenib, as a neoadjuvant
treatment in a 21-year-old male prior to surgery and found a 9 80%
reduction of tumor size [86].
However, to further evaluate the efficacy of and tumor resistance to these
BRAF and MEK targeting agents, the results of prospective clinical trials are
needed. Currently, the neoadjuvant treatment combination of BRAF inhibitor,
vemurafenib, with the MEK inhibitor, cobimetinib, is being evaluated in a
phase II trial in patients harboring BRAF V600E mutated craniopharyngiomas
(NCT03224767).
WNT/β-Catenin Signaling and MEK Inhibitors in ACP
The most frequently observed mutations in ACPs are located in the
CTNNB1 gene (encoding β-catenin) [87]. These mutations affect regula-
tory amino acids that include phosphorylation sites that normally allow
quick degradation of β-catenin. By consequence, β-catenin accumulates
and mediates WNT pathway signaling. Even though the majority of
ACPs have somatic activating mutations in CTNNB1, the cellular accu-
mulation of β-catenin is limited to only a small proportion of cells
(referred to as β-catenin-accumulating cell clusters) [88••, 89]. Insight
into the functional significance of the β-catenin-accumulating cell clus-
ters suggest that these cells potentially drive tumor growth and invasion
into the surrounding tissue by secretion of factors (e.g., fibroblast
growth factor (FGF), epithelial growth factor (EGF), and platelet-
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derived growth factor (PDGF)) in a paracrine manner [88••, 89]. Along
these lines, Apps et al. were able to show that even though ACPs do not
carry mutations in the MAPK pathway components, this pathway was
activated in mice and human APC cells next to these paracrine active
cluster cells [88••].
One in vitro study inhibiting the MAPK pathway in APCs using the MEK
inhibitor, trametinib, demonstrated reduced proliferation and increased apo-
ptosis in bothmouse and human ACP tumors [88••]. These results suggest that
MEK inhibition could also provide a clinically viable treatment in ACP tumors.
Unfortunately, the direct inhibition of the activated WNT/β-catenin path-
way has not been translated into novel targeted therapies yet, due to the
difficulty of targeting this pathway without causing unacceptable toxicity [90].
IL-6 Receptor Inhibitor in ACP
Other transcriptional molecular analyses of ACPs have revealed a high expres-
sion of immune-related genes. Beside other immunomodulators, these studies
demonstrated highly upregulated levels of IL-6 receptor (IL-6R) and IL-6 in cyst
fluid and solid tumor tissue, suggesting a critical role in ACP pathogenesis [91,
92]. From a therapeutic perspective, IL-6R can be targeted by tocilizumab, a
humanized monoclonal antibody, that has already been used in pediatric
oncology (FDA approved for children older than 2 years for the treatment of
juvenile idiopathic arthritis and cytokine release syndrome).
Grob et al. recently reported the first use of tocilizumab alone or in combina-
tion with bevacizumab for the treatment of cystic ACP in two pediatric patients. In
both cases, the cystic portion of the tumor responded. When the patient on
tocilizumabmonotherapy progressed, bevacizumab was added as a cystic targeted
therapy. Even though the role of bevacizumab as a monoclonal antibody that
binds to vascular endothelial growth factor (VEGF) and results in inhibition of new
blood vessel formation remains unclear in ACP patients [93], clinical benefit was
seen in these patients. An early phase 1 trial with tocilizumab for childrenwith ACP
has been initiated with the first phase of the trial to confirm that drug is able to
reach the tumor. If the clinical results are favorable and tocilizumab shows pene-
tration of the tumor, the trial will expand to a feasibility phase, where tocilizumab
will be administered every 2 weeks for up to 2 years (NCT03970226).
Medulloblastomas
Medulloblastomas (MB) are highly aggressive (WHO grade IV) embryonal tumors
of the posterior fossa and comprise 15–20% of pediatric CNS tumors, making up
the most common malignant pediatric brain tumor [3]. Classification into four
molecular subgroups (wingless-activated [WNT], sonic hedgehog-activated [SHH],
Group 3, and Group 4) has improved treatment stratification and provided
rationale for introduction of targeted therapies (Table 1) [94–96]. Standard therapy
for medulloblastoma comprises surgical resection, craniospinal irradiation (for
children 9 3–5 years of age), and multiagent chemotherapy. However, novel
treatment strategies are greatly needed to reduce treatment-related morbidity and
provide curative options for high-risk patients, including those with metastatic
dissemination, TP53-mutated/SHHMB, or relapsed/progressive MB.
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Inhibitors of the SHH Pathway
The sonic hedgehog (SHH) pathway has been the most explored in MB
and thus far numerous targets have been identified [97] (Fig. 1). SHH
MB are prevalent across the entire age spectrum, with a bimodal distri-
bution and age peaks in both infancy and adulthood. There are four
molecular subtypes within the SHH subgroup, each with distinct clinical
characteristics and outcome [96]. Whereas adult SHH MB are typically
driven by PTCH, SMO mutations, and/or TERT promoter mutations,
infant SHH MB comprise 2 subtypes, including a group of patients with
poor prognosis harboring alterations such as SUFU mutations and PTEN
loss. School-aged children, on the other hand, commonly have TP53
mutations, which are associated with very high risk of treatment failure
and early relapse [98]. SHH MB in adolescents and adult patients also
commonly harbor mutations of U1 spliceosomal small nuclear RNAs
(snRNAs) [99].
Given the heterogeneity within SHH-driven MB, multiple targeted or
combination treatment strategies are warranted. The first targeted thera-
pies to advance into clinical trials were the smoothened receptor (SMO)
inhibitors, which target the SHH signaling pathway early in transduction
[100–102]. Vismodegib (GDC-0449) and sonidegib (LDE225), both
SMO inhibitors, have been investigated for their use in recurrent SHH-
driven medulloblastoma and the addition of vismodegib to standard
chemotherapy is currently being investigated for selected, newly diag-
nosed SHH MB patients (SJMB12; NCT01878617). In a meta-analysis
evaluating clinical trials of vismodegib and sonidegib, both inhibitors
were well tolerated and showed antitumor activity against SHH MB but
not against other MB subgroups. In this study, sonidegib appeared to
have higher efficacy, especially in pediatric patients [103•]. Unlike adult
MB, infant and childhood SHH-driven MB often exhibit mutations
downstream of PTCH and are thus unlikely to respond to SMO inhib-
itors [104]. Furthermore, inhibition of growth plate fusion upon treat-
ment with these agents raises concern for their application in children
[105, 106••] and acquired resistance is frequent, limiting their use as a
monotherapy [107].
Alternative targeting strategies focusing on other downstream targets, such as
GLI transcriptional factors, or combination therapies, are in development [108–
110]. Arsenic trioxide (ATO), which is already approved by the FDA for treat-
ment of acute promyelocytic leukemia, interferes with GLI transcription factors
and in combination with itraconazole has shown efficacy in vitro and in vivo in
SMO inhibitor-resistant medulloblastoma [109, 111]. Casein kinase 2 (CK2) is
critical for GLI2 activity in SHH-driven medulloblastoma, and CK2 inhibitors
were shown to impair proliferation [112] and sensitize MB cells to temozolo-
mide [113]. One of these inhibitors, silmitasertib (CX-4945), is currently being
tested in a phase I/II trial for recurrent SHH-MB (NCT03904862). Development
of specific inhibitors for CDK 4/6 also offers potential use in treatment of
medulloblastoma [114]. An ongoing phase I trial (NCT03434262) investigates
several combination therapies for recurrent pediatric CNS tumors, including
CDK 4/6 inhibitor ribociclib in combination with trametinib or sonidegib for
SHH MB.
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Targeting MYC-Amplified Medulloblastomas
Children with Group 3, MYC-amplified MB commonly present with metastatic
disease and respond poorly to current treatment protocols. Using MYC-driven
murine and human MB cell models, high-throughput drug profiling studies have
identified the combination of pemetrexed and gemcitabine [115] as well as antag-
onists of the PI3K and HDAC pathway [116] as promising agents for treatment of
MYC-driven MBs. Pemetrexed and gemcitabine are currently being investigated in
newly diagnosed patients with Group 3 and Group 4 MB (NCT01878617).
In a subset of Group 3 and Group 4 MBs, tumors are driven by MYC in
cooperation with growth factor independent genes GFI1 and GFI1B, which are
overexpressed due to “enhancer hijacking” events [117]. These tumors critically
depend on lysine-specific histone demethylase (LSD1) function in order to
block genes for neural commitment and differentiation [118]. Genetic ablation
of this enzyme impairs tumor growth in vivo; hence LSD1 inhibitors may be
another therapeutic strategy for Group 3 and 4, GFI-driven MB.
Epigenetic Drivers as Targets in Medulloblastoma
Other strategies targeting epigenetic alterations have been explored in medul-
loblastoma. Histone demethylase, KDM6A, is found to be mutated in Group 4
medulloblastoma resulting in elevated H3K27me3 and recruitment of repres-
sive PRC2 complex, with EZH2 as its catalytic subunit (Fig. 1). This recruitment
represses lineage differentiation genes and leads tomaintenance of proliferative
stem cell signatures [119]. Overexpression of EZH2 and subsequent repression
of tumor suppressor genes has been found in many cancers, including non-
WNT/non-SHH medulloblastoma [120]. Several EZH2 inhibitors show anti-
cancer effects in cell lines and mouse models [121] and the EZH2 inhibitor,
tazemetostat, is in a clinical phase 2 trial for a variety of recurrent tumors in
children, including medulloblastoma (NCT03155620).
Having a near ubiquitous role in cancers, HDACs belong to the best studied
epigenetic modifiers. Several HDAC inhibitors are in clinical trials for pediatric
brain tumors (mostly HGG/DMG, as discussed above). For medulloblastoma,
HDAC2 has been observed to be overexpressed in SHH, Group 3, and Group 4
subgroups, and its ablation reduced tumorgenicity in cell lines [122]. Fimepi-
nostat, a dual HDAC and PI3K Class I inhibitor, is currently under investigation
in a target validation clinical trial to assess blood-brain barrier penetration in
children with pediatric brain tumors, including children with recurrent medul-
loblastoma (PNOC016; NCT03893487).
BET family of bromodomain proteins recognize histone acetylation and
trigger gene expression, including super-enhancer-regulated cancer genes
[123]. The BET protein inhibitor, JQ1, represses tumor growth in SHH-
medulloblastoma cells, by reducing GLI1 and GLI2 expression [124]. Similar
effects are seen in Group 3 medulloblastoma cells, where BET inhibition leads
to downregulation ofMYC expression [125]. Other BET inhibitors are currently
under investigation for pediatric solid tumors (NCT03936465).
Discussion
Over the recent years, our understanding of the molecular biology of pediatric
brain tumors has vastly improved. This has led to more narrowly defined
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subgroups of these tumors and created new potential targets for molecularly
driven therapies, even extending to tumors that have historically been treated
with surgery and radiotherapy, such as craniopharyngiomas. Further, since the
early 2000s, initial successes in the clinical implementation of targeted therapy
such as everolimus for SEGAs have been demonstrated. However, the promis-
ing advances in targeted therapies for pediatric brain tumors also lead to
challenges that the pediatric neuro-oncology community still has to address.
Enhancing Drug Delivery to the Brain Tumor
In order to identify effective targeted therapies, the blood-brain barrier (BBB)
penetration and the distribution within the brain and tumor tissue need to be
considered. A number of different strategies have been developed to overcome
these barriers and improve the delivery of therapeutic agents to cancer cells. These
methods range from chemically disrupting the BBB itself tomodifying the therapy
agents and their carriers [126]. Another emerging and promising method entails
the temporary mechanical opening of the BBB in a targeted and localized manner
by MR-guided focused ultrasound (MRgFUS) to support drug delivery [127]. An
alternative strategy to deliver drugs directly into the tumor tissue, bypassing the
BBB entirely, is performed by convection-enhanced delivery (CED) through ster-
eotactically placed catheters [70]. Broad applications of such targeted deliveries are
still missing, but early studies support feasibility and safety [128].
Clinical Study Endpoints Beyond Tumor Response
With the growing number of targeted therapies entering the clinic, it is critical to
define appropriate endpoints to assess therapy responses as well as short- and
long-term toxicities. Currently, therapy response in clinical trials for pediatric brain
tumors is mainly based on radiographic tumor response and clinical endpoints
like overall survival (OS), progression-free survival (PFS), or event-free survival
(EFS) depending on the specific tumor type. Functional outcomes, such as oph-
thalmologic, neurocognitive, neurofunction, and quality of life (QOL) assess-
ments, are often not included as primary study endpoints. These endpoints
though, potentially having more direct patient relevance, especially since image-
based responses remain challenging to evaluate correctly in many pediatric tumor
types. Additionally, while other exciting upcomingmodalities, e.g. patient derived
liquid biopsy analysis, may help to more adequately predict early tumor response
[129], they lack sufficient assessment of the functional response to therapy and
QOL aspects for the growing and developing child. Therefore, to help providers
and patients perform more accurate risk/benefit analyses when deciding and
comparing therapeutic options, incorporation of functional endpoints and QOL
assessments into clinical trial design will be crucial.
Resistance Mechanisms and Combinational Targeted Therapies
Strong driver mutations, such as the commonly altered MAPK pathway in
pLGG, have been proven to be a particularly good target for direct inhibitors
such as MEK inhibitors. However, despite clear response rates in this setting,
many questions remain unsolved: What is the optimal dosing? How long
should patients be treated with these targeted inhibitors? What are the mecha-
nisms of resistance and how can these be overcomewith potential combination
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strategies? Aside from pLGGs, most other pediatric CNS tumors exhibit sub-
stantially greater molecular heterogeneity and likely various tumor driver alter-
ations or yet unknown drivers. Hence, wide genomic profiling for these tumors
will be crucial for correct subclassification and implementation of targeted
treatment strategies. There are now many examples that such assessments can
be integrated in real time and should be considered the standard. Even for
entities that generally only allow the collection of small stereotactic biopsies
such as DIPG, genomic-based, real-time multiagent therapy approaches for
treatment are feasible [7]. The increased understanding of the molecular make
up of tumors allows response assessment in a defined context, which will be
critical for future successes.
Conclusion
The field of pediatric neuro-oncologymade tremendous progress with regard to
improved diagnosis setting the stage for precisionmedicine approaches over the
last decades. The potential of targeted therapies has been clearly demonstrated
for a subset of pediatric brain tumors. However, despite clear response rates,
questions of sufficient blood-brain barrier penetration, optimal dosing, treat-
ment duration, as well as mechanisms of resistance and how these can be
overcome with potential combination strategies need to be addressed in future
investigations. Along this line, it is critical for future trials to define appropriate
endpoints to assess therapy responses as well as short- and long-term toxicities
in the growing and developing child.
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